Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients

Journal of Infectious Diseases

Volumn 207, Issue 10, 2013, Pages 1569-1575

  Courivaud, Cécile ^a,b,c   Bamoulid, Jamal ^a,b,c   Chalopin, Jean Marc ^a,b,c,d   Gaiffe, Emilie ^d   Tiberghien, Pierre ^a,b,d,e   Saas, Philippe ^a,b,d,e   Ducloux, Didier ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c HÔPITAL SAINT JACQUES   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

cardiovascular disease; cytomegalovirus; kidney transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; C REACTIVE PROTEIN; COTRIMOXAZOLE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS REPLICATION;

ADULT; CARDIOVASCULAR DISEASES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; VIRUS REPLICATION;

EID: 84876563425     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit064     Document Type: Article

References (31)

1. Nieto FJ, Adam E, Sorlie P, et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996; 94:922-7. (Pubitemid 26292841)
2. Sorlie PD, Nieto FJ, Adam E, et al. A Prospective Study of Cytomegalovirus, Herpes Simplex Virus 1, and Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2000; 160:2027-32. (Pubitemid 30437586)
3. Smieja M, Gnarpe J, Lonn E, et al. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107:251-7. (Pubitemid 36135220)
4. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261:3561-6. (Pubitemid 19155945)
5. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100:61-6. (Pubitemid 29297941)
6. Melnick JL, Petrie BL, Dreesman GR, et al. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983; 2:644-7. (Pubitemid 13003484)
7. Melnick JL, Hu C, Burek J, Adam E, DeBakey ME. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol 1994; 42:170-4. (Pubitemid 24077560)
8. Epstein SE, Zhu J, Najafi AH, Burnett MS. Insights into the role of infection in atherogenesis and in plaque rupture. Circulation 2009; 119:3133-41.
9. Stassen FR, Vega-Cordova X, Vliegen I, Bruggeman CA. Immune activation following cytomegalovirus infection: more important than direct viral effects in cardiovascular disease? J Clin Virol 2006; 35:349-53. (Pubitemid 43188987)
10. Reinhardt B, Mertens T, Mayr-Beyrle U, et al. HCMV infection of human vascular smooth muscle cells leads to enhanced expression of functionally intact PDGF beta-receptor. Cardiovasc Res 2005; 67:151-60. (Pubitemid 40798302)
11. van Dam-Mieras MC, Muller AD, et al. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost 1992; 68:364-70.
12. Pawelec G, Derhovanessian E, Larbi A, Strindhall J, Wikby A. Cytomegalovirus and human immunosenescence. Rev Med Virol 2009; 19:47-56.
13. De Keyzer K, Van Laecke S, Peeters P, Vanholder R. Human cytomegalovirus and kidney transplantation: a clinician's update. Am J Kidney Dis 2011; 58:118-26.
14. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011; 378:1419-27.
15. Humar A, Gillingham K, Payne WD, Sutherland DE, Matas AJ. Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation 2000; 70:310-3. (Pubitemid 30602749)
16. Ducloux D, Challier B, Saas P, et al. CD4 cell lymphopenia and atherosclerosis in renal transplant recipients. J Am Soc Nephrol 2003; 14:767.
17. Derhovanessian E, Larbi A, Pawelec G. Biomarkers of human immunosenescence: impact of cytomegalovirus infection. Curr Opin Immunol 2009; 21:440-45.
18. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-9. (Pubitemid 27152782)
19. Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990; 136:23-8. (Pubitemid 20034949)
20. Pawelec G, Akbar A, Caruso C, Effros R, Grubeck-Loebenstein B, Wikby A. Is immunosenescence infectious? Trends Immunol 2004; 25:406-10. (Pubitemid 38951080)
21. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20:2275-83. (Pubitemid 44789529)
22. Sacre K, Hunt PW, Hsue PY, et al. A role for cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. AIDS 2012; 26: 805-14.
23. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation predicts carotid artery stiffness in HIV-infected women. Atherosclerosis 2011; 217:207-13.
24. Betjes MGH, Litjens NHR, Zietse R. Seropositivity for cytomegalovirus in patients with end-stage renal disease is strongly associated with atherosclerotic disease. Nephrol Dial Transplant 2007; 22: 3298-303. (Pubitemid 350202544)
25. Betjes MGH, Langerak AW, van der Spek A, de Wit EA, Litjens NHR. Premature aging of circulating T cells in patients with end-stage renal disease. Kidney Int 2011; 80:208-17.
26. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One 2011; 6:e16103.
27. Wikby A, Johansson B, Olsson J, Löfgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol 2002; 37: 445-53. (Pubitemid 34073563)
28. Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol 2010; 172:363-71.
29. Strindhall J, Nilsson BO, Löfgren S, Ernerudh J, Pawelec G, Johansson BWikby A. No immune risk profile among individuals who reach 100 years of age: findings from the Swedich NONA immune longitudinal study. Exp Gerontol 2007; 42:753-61. (Pubitemid 47058867)
30. Spinner ML, Saab G, Casabar E, et al. Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation 2010; 90:412-8.
31. Kall AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870-80. (Pubitemid 46202222)